Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 11—November 2023
Synopsis

Clinical Manifestations and Genomic Evaluation of Melioidosis Outbreak among Children after Sporting Event, Australia

Simon SmithComments to Author , Tonia Marquardt, Amy V. Jennison, Andrew D’Addona, James Stewart, Trent Yarwood, Jennifer Ho, Enzo Binotto, Julian Harris, Mark Fahmy, Juliet Esmonde, Megan Richardson, Rikki M.A. Graham, Richard Gair, Lawrence Ariotti, Annie Preston-Thomas, Sally Rubenach, Siobhan O’Sullivan, Darren Allen, Thomas Ragh, Sachjuan Grayson, Sophie Manoy, Jeffery M. Warner, Ella M. Meumann, Jennifer M. Robson, and Josh Hanson
Author affiliations: Cairns Hospital, Cairns, Queensland, Australia (S. Smith, J. Stewart, T. Yarwood, J. Ho, E. Binotto, J. Harris, M. Fahmy, S. O’Sullivan, T. Ragh, S. Grayson, S. Manoy, J. Hanson); Cairns & Hinterland Health Service, Cairns (T. Marquardt, A. D’Addona, J. Esmonde, M. Richardson, R. Gair, A. Preston-Thomas, S. Rubenach); Forensic and Scientific Services, Brisbane, Queensland, Australia (A.V. Jennison, R.M.A. Graham, L. Ariotti); University of Queensland, Herston, Queensland, Australia (T. Yarwood); James Cook University, Cairns (T. Yarwood, J. Ho); Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia (D. Allen); James Cook University, Townsville, Queensland, Australia (J.M. Warner); Sullivan Nicolaides Pathology, Bowen Hills, Queensland, Australia (E.M. Meumann, J.M. Robson); Menzies School of Health Research, Darwin, Northern Territory, Australia (E.M. Meumann); University of New South Wales, Sydney, Australia (J. Hanson)

Main Article

Table 1

Clinical features, antimicrobial drug treatment, and outcomes of limited cutaneous melioidosis among children after sporting event, Australia*

Case no. Age, y/sex Location of cutaneous lesion(s) No. swabs† Immunocompetent Disseminated foci excluded‡ Intensive phase duration Eradication phase duration§ Primary antimicrobial drug# Outcome
1
 8/F
 Left arm, right leg, low back
 1
 Y
 Y
 14 d
 9 d
 Ceftazidime
 Recovered
2
 8/F
 Right leg, left leg
 2
 Y
 Y
 2 d
 12 wk
 AMOX/CLAV
 Recovered
3
 10/F
 Abdomen
 1
 Y
 Y
 NA
 8 wk
 Doxycycline
 Recovered
4
 7/M
 Left arm
 1
 Y
 Y
 NA
 17 d
 AMOX/CLAV
 Recovered
5
 7/M
 Right arm
 2
 Y
 Y
 NA
 12 wk
 AMOX/CLAV
 Recovered
6
 7/F
 Right arm
 1
 Y
 Y
 NA
 9 wk
 Doxycycline
 Recovered
7 9/F Right hip 1 Y Y NA 12 wk AMOX/CLAV Recovered

*AMOX/CLAV, amoxicillin/clavulanate. NA, not applicable. †Number of swab samples collected before Burkholderia pseudomallei was cultured. ‡Defined by no B. pseudomallei growth in blood cultures, and no evidence of infection on chest radiograph and abdominal ultrasound. §Defined as total duration of antimicrobial drug course, excluding treatment interruptions. #Antimicrobial drug used for longest time.

Main Article

Page created: September 14, 2023
Page updated: October 23, 2023
Page reviewed: October 23, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external